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(±)-cis-4,40-Dimethylaminorex (4,40-DMAR) is a new psychoactive substance (NPS) that has been asso-
ciated with 31 fatalities and other adverse events in Europe between June 2013 and February 2014. We
used in vitro uptake inhibition and transporter release assays to determine the effects of 4,40-DMAR on
human high-afﬁnity transporters for dopamine (DAT), norepinephrine (NET) and serotonin (SERT). In
addition, we assessed its binding afﬁnities to monoamine receptors and transporters. Furthermore, we
investigated the interaction of 4,40-DMAR with the vesicular monoamine transporter 2 (VMAT2) in rat
phaeochromocytoma (PC12) cells and synaptic vesicles prepared from human striatum. 4,40-DMAR
inhibited uptake mediated by human DAT, NET or SERT, respectively in the low micromolar range (IC50
values< 2 mM). Release assays identiﬁed 4,40-DMAR as a substrate type releaser, capable of inducing
transporter-mediated reverse transport via DAT, NET and SERT. Furthermore, 4,40-DMAR inhibited both
the rat and human isoforms of VMAT2 at a potency similar to 3,4-methylenedioxymethylamphetamine
(MDMA). This study identiﬁed 4,40-DMAR as a potent non-selective monoamine releasing agent. In
contrast to the known effects of aminorex and 4-methylaminorex, 4,40-DMAR exerts profound effects on
human SERT. The latter ﬁnding is consistent with the idea that fatalities associated with its abuse may be
linked to monoaminergic toxicity including serotonin syndrome. The activity at VMAT2 suggests that
chronic abuse of 4,40-DMAR may result in long-term neurotoxicity.
© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).hylaminorex; 4-MAR, 4-
nsporter; GAT1, gamma-ami-
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r Ltd. This is an open access article1. Introduction
In recent years, an increasing number of new psychoactive
substances (NPS) appeared on the recreational drug markets. NPS
mimic the effects of established drugs of abuse, ranging from can-
nabinoids to psychostimulants (UNODC, 2017). Typically,
the pharmacology is poorly characterized and adverse clinical ef-
fects are often associated with their abuse (Baumann and Volkow,
2016). (±)-cis-4,40-dimethylaminorex ((±)-cis-4-methyl-5-(4-methyl
phenyl)-4,5-dihydro-1,3-oxazol-2-amine, 4,40-DMAR) represents aunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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is scarce. 4,40-DMAR is derived from drug development efforts in the
search for potential anorectic medicines such as aminorex (Poos
et al., 1963). In 2012, 4,40-DMAR was identiﬁed in the Netherlands
and reported to the EuropeanMonitoring Center for Drugs and Drug
Addiction (EMCDDA). Between June 2013 and February 2014, 4,40-
DMAR has been analytically conﬁrmed and linked to 31 deaths
(EMCDDA, 2015; Brandt et al., 2014).
So far, the chemical features of 4,40-DMAR and its releasing ac-
tivity at monoamine transporters in rat brain synaptosomes have
been reported (Brandt et al., 2014; McLaughlin et al., 2015). Psy-
chostimulants that target the high-afﬁnity transporters for mono-
amines can act in two different modes: as (i) non-transported
inhibitors (e.g. cocaine) or (ii) they can be recognized as substrates,
often referred to as “amphetamine-type” drugs or “releasers” (Sitte
and Freissmuth, 2015). The latter “invert” the physiological trans-
port direction of the transporters which results in transporter-
mediated release of neurotransmitters. It has been reported that
4,40-DMAR induced release via rat DAT (SLC6A3), NET (SLC6A2) and
SERT (SLC6A4) and hence, the compound was classiﬁed a “releaser”
(Brandt et al., 2014).
In comparison to its congeners aminorex and 4-MAR ((±)-cis-4-
methylaminorex), 4-40-DMAR has been shown to be a more potent
releaser at SERT (Brandt et al., 2014). The pharmacological effects of
all three compounds resemble those of amphetamine (Hofmaier
et al., 2014; Kankaanp€a€a et al., 2001; Rothman et al., 1999). How-
ever, aminorex (DAT/SERT ratio¼ 45) and 4-MAR (DAT/SERT ra-
tio¼ 31) were found to be more catecholamine-selective compared
to 4,40-DMAR (DAT/SERT ratio¼ 2) (Brandt et al., 2014).
In 2014, a risk assessment carried out on 4,4-DMAR by the
EMCDDA revealed that the clinical features associated with the
reported adverse effects were consistent with serotonin and car-
diovascular toxicity and that combinations of 4,40-DMAR with
various other drugs also targeting the monoaminergic systemwere
thought to have played a contributory role in the fatalities
(EMCDDA, 2015). During the following years, 4,40-DMAR was crit-
ically reviewed by theWorld Health Organization and subsequently
controlled internationally and listed in Schedule II of the Conven-
tion on Psychotropic Substances of 1971 (UNODC, 2016).
In the present study, we attempted to provide the ﬁrst complete
pharmacological characterization of 4,40-DMAR's interaction with
human plasmalemmal monoamine transporters: Speciﬁcally, we
examined the interplay between 4,40-DMAR and the most relevant
monoamine receptors and transporters in terms of uptake inhibi-
tion and releasing action, as well as their binding proﬁle. Further-
more, we performed two different approaches to investigate the
inhibitory properties of 4,40-DMAR at human and rat VMAT2. Per-
turbations of VMAT2 function have been associated with neuro-
toxicity and depletion of brain monoamines (German et al., 2015).
Considering the inhibitory effects at VMAT2 and its activity as
substrate at DAT, NET and SERT may provide a molecular explana-
tion for the adverse clinical effects associated with 4,40-DMAR.
2. Materials and methods
2.1. Reagents and chemicals
(±)-cis-4,40-DMAR hydrochloride was available from previous
studies (Brandt et al., 2014). Reagents used in the experiments for
uptake inhibition and release in HEK293 cells were used as
described in Hofmaier et al. (2014). For uptake and release exper-
iments [3H]1-methyl-4-phenylpyridinium ([3H]MPPþ; 80e85 mCi x
mmol1) was purchased from American Radiolabeled Chemicals
(St. Louis, MO, USA). [3H]Dopamine (55 mCi x mmol1), [3H]GABA
(89,7 mCi x mmol1), [3H]5-HT (28.3 mCi x mmol1), [3H]8-OH-DPAT, [3H]ketanserin, [3H]mesulergine, [3H]prazosin, [3H]rau-
wolscine, [3H]spiperone, N-methyl-[3H]nisoxetine, [3H]WIN35,428,
and [3H]citalopram were all from Perkin Elmer (Boston, MA, USA).
[3H]RO5166017 and RO5166017 were provided from F. Hoffmann-
La Roche (Basel, Switzerland). All other chemicals and cell culture
supplies were ordered from Sigma-Aldrich (St. Louis, MO, USA)
with the exception of cell culture dishes, which were obtained from
Sarstedt (Nuembrecht, Germany).
2.2. Cell culture
Human embryonic kidney (HEK293) cells, used for uptake in-
hibition and superfusion release assays, were maintained in a hu-
midiﬁed atmosphere (37 C and 5% CO2) at a subconﬂuential state
in Dulbecco's Modiﬁed Eagle Medium (DMEM) supplemented with
10% heat-inactivated Fetal Bovine Serum (FBS), penicillin (100 U x
100mL1) and streptomycin (100 mg x 100mL1). Geneticin (50 mg
x mL1) was added to maintain the selection process. The genera-
tion of stable, monoclonal cell lines is described elsewhere (Mayer
et al., 2016a). Twenty-four hours prior to uptake inhibition exper-
iments, HEK293 cells expressing the desired transporter, were
seeded at a density of 40,000 cells per well onto poly-D-lysine (PDL)
coated 96-well plates in a ﬁnal volume of 200 mL per well. Analo-
gously, 24 h before release experiments, 40,000 cells per well were
seeded onto poly-D-lysine coated glass coverslips (5mm in diam-
eter), that have been placed into a 96-well plate for a ﬁnal volume
of 200 mL per well (Mayer et al., 2016a).
Cells used for receptor and transporter binding assays and re-
ceptor activation assays, were cultured and prepared as recently
described in detail (Luethi et al., 2017a). For membrane prepara-
tions, the cells were harvested following application of trypsin/
ethylenediaminetetraacetic acid (EDTA), washed with ice-cold PBS,
pelleted via centrifugation (1000 rpm for 5min at 4 C), frozen and
stored at 80 C. The frozen pellets were then suspended in 20mL
(receptor binding) or 400mL (transporter binding) HEPES-NaOH
(20mM, pH 7.4) containing 10mM EDTA. After homogenization
at 14,000 rpm for 20 s (receptor binding) or 10,000 rpm for 15 s
(transporter binding), the homogenates were centrifuged at
48,000 g and 4 C for 30min. For receptor binding assays, super-
natants were discarded and the pellets resuspended in 20mL
HEPES-NaOH (20mM, pH 7.4) containing 0.1mM EDTA and ho-
mogenized at 14,000 rpm for 20 s. The centrifugation and removal
of the supernatant was repeated, and the ﬁnal pellet was resus-
pended in HEPES-NaOH that contained 0.1mM EDTA and homog-
enized. The following transfected cell lines were used for the
binding assays: HEK293 cells (5-HT1A, 5-HT2A, 5-HT2C, TAAR1, D2,
hDAT, hNET, and hSERT), Chinese hamster ovary (CHO) cells (a1A),
and Chinese hamster lung (CHL) cells (a2A).
Rat pheochromocytoma cells (rPC12), used for VMAT2 uptake
inhibition assays, were grown in PDL-coated cell culture dishes
(10 cm diameter) in Opti-MEM (Gibco), supplemented with 5%
Fetal Bovine Serum (FBS) and 10% horse serum, penicillin (100 U x
100mL1) and streptomycin (100 mg x 100mL1). For VMAT2-
assays, the cells were seeded at 40,000 cells per well onto PDL
coated 96-well plates in a ﬁnal volume of 200 mL per well 24 h
beforehand.
The human striatal tissue was derived from autopsied frozen
half brains of subjects without evidence of any neurological or
psychiatric disorder in their records as described earlier (Piﬂ et al.,
2015).
2.3. Uptake inhibition assays
For uptake inhibition experiments, DMEM was removed from
the cell culture dishes and replaced with Krebs-HEPES-buffer (KHB;
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MgSO4 and 5mM D-glucose, pH adjusted to 7.3) at a ﬁnal volume of
200 mL per well. The cells were exposed to increasing concentra-
tions of 4,40-DMAR, diluted in KHB, and 3,4-
methylendioxymethylamphetamine (MDMA), diluted in Milli-Q
H2O, at a ﬁnal volume of 200 mL per well for 10min to ensure
equilibrated conditions. This was the case for hSERT, hDAT, hNET
transfected HEK cells as well as rat GAT1 (SLC6A1), expressed in
HEK293 cells. For the 4,40-DMAR experiments, tritiated substrate
(0.2 mM [3H]5-HT for hSERT, 0.01 mM [3H]MPPþ for hDAT and hNET,
0.15 mM [3H]GABA for rGAT1) was added after 10min. Tritiated
substrate utilized in theMDMAuptake inhibition assays was 0.2 mM
[3H]5-HT for hSERT, 0,2 mM [3H]DOP for hDAT and 0,015 mM [3H]
MPPþ for hNET. Uptake was terminated after 60 s for hSERT and
180 s for hDAT, hNET and rGAT1 by removing the tritiated substrate
and washing the cells with 200 mL of ice-cold KHB. Afterwards, the
cells were lysed in 100 mL 1% sodium dodecyl sulfate (SDS) per well.
Uptake of tritiated substrate was determined with a beta-
scintillation counter (Perkin Elmer, Waltham, MA, USA). In the
4,40-DMAR assays, non-speciﬁc uptake was assessed in presence of
10 mM paroxetine for SERT, 10 mM mazindole for hDAT, 10 mM
nisoxetine for NET and 10 mM tiagabine for rGAT1. For the MDMA
assays, non-speciﬁc uptake was assessed in presence of 100 mM
paroxetine for SERT, 30 mM cocaine for hDAT and 1000 mM cocaine/
methylendioxypyrovaleron (MDPV) for NET. Non-speciﬁc uptake
was subtracted from the data to yield speciﬁc uptake values. Uptake
in the absence of test drugs was deﬁned as 100% and uptake in the
presence of drugs was expressed as a percentage thereof. The half
maximal inhibitory concentration was determined by non-linear
regression ﬁts according to the equation: [Y¼Bottom þ (Top-Bot-
tom)/(1þ10 [^(X-LogEC50])*HillSlope))] (Mayer et al., 2016a). rGAT1
expressing HEK293 cells were used as a negative control because
amphetamines and amphetamine-type substances display no ac-
tivity at GAT1 at pharmacologically relevant concentrations (Seidel
et al., 2005).
Uptake into permeabilized PC12 cells attached to PDL-coated
96-well plates was measured as described earlier (Nakanishi
et al., 1995), with minor modiﬁcations. PC12 cells were pre-
incubated with 150 mM digitonin for 15min at room temperature
to permeabilize cell membranes. Subsequently, the cells were
washed with HTMS buffer (50mM Hepes-Tris buffer, 6mM MgCl2,
0.32M sucrose, 2mM ATP, pH 7.4 e adjusted with MgOH2)
(Nakanishi et al., 1995). Hundred nM nisoxetine and 100 nM
mazindole were added to the buffer to inhibit DAT and NET. The
cells were exposed to increasing concentrations of 4,40-DMAR,
MDMA or reserpine, diluted in HTMS buffer, at a ﬁnal volume of
200 mL per well for 5min. Subsequently, tritiated substrate (0.1 mM
[3H]5-HT) was added. Uptake was terminated after 15min by
aspirating the tritiated substrate and washing the cells with 200 mL
ice-cold HTMS buffer. Afterwards, the cells were lysed with 100 mL
1% SDS per well. This solution was then transferred into counting
vials, containing 2mL scintillation cocktail. Uptake was determined
with a beta-scintillation counter (Perkin Elmer, Waltham, MA,
USA). Non-speciﬁc uptake was determined in presence of 1 mM
reserpine and subtracted from the data to yield speciﬁc uptake
values. Uptake in the absence of test drugs was deﬁned as 100% and
uptake in the presence of drugs was expressed as a percentage of
control uptake. The half maximal inhibitory concentration was
determined as mentioned above.
To evaluate VMAT2 uptake inhibition in human striatal tissue,
seven samples were derived from autopsied frozen half brains. The
specimens originated from voluntary body donations (6 females, 1
male, aged 87± 8 years) to the Center of Anatomy and Cell Biology,
Medical University of Vienna, and were required to show no evi-
dence of any neurological or psychiatric disorder in their records,similar to a previous publication (Piﬂ et al., 2015). 600mg of striatal
tissue were then homogenized in ice-cold 0.3M sucrose containing
25mM Tris (pH 7.4) and 10 mM pargyline in a glass Teﬂon Potter-
type homogenizer. Vesicles in the supernatants of P2-pellets of a
synaptosomal preparation and in H2O-lysates of P2-pellets were
combined as described recently (Piﬂ et al., 2014) and stored
at 80 C until uptake analysis. Uptake was performed in a total
volume of 1.5mL 0.13M potassium phosphate buffer (pH 7.4),
containing 2mM MgATP, 0.1 mM of [3H]dopamine and various
concentrations of DMAR, at 30 C for 4min as recently described
(Piﬂ et al., 2014).
2.4. Transporter release assays
Our dynamic transporter release assays allow for the assess-
ment of monoamine-transporter-mediated reverse transport and
avoid reuptake or retrograde diffusion of tritiated substrates by
using a constant ﬂow rate that causes the clearance of released
substances (Piﬂ et al., 1995; Steinkellner et al., 2016; Mayer et al.,
2016a). In brief, transporter-expressing cells are grown on glass-
coverslips and pre-loaded with tritiated substrate by exposing the
cells to 0.4 mM [3H]5-HT (hSERT), 0.1 mM [3H]MPPþ (hDAT), 0.05 mM
[3H]MPPþ (hNET) or 0.1 mM [3H]GABA (rGAT1), respectively, for
20min at 37 C. Subsequently, the cells are transferred into small
chambers and superfused with KHB (0.7mLmin1). The super-
fusates are collected in counting vials (10mL), containing 2mL
scintillation cocktail. After a cycle of 2min, the next set of vials is
automatically ﬁlled. The tubes delivering the drug-containing
buffer are submerged in a water bath with a constant tempera-
ture of 25 C. To establish a stable basal release, the cells were
superfused for 40min before the collection of 2-min fractions was
initiated. At ﬁrst, three basal fractions were collected before the
cells were exposed to monensin (10 mM) or solvent for four frac-
tions. The Naþ/Hþ ionophore monensin was chosen because it
disrupts the pre-existing sodium gradient. The examined trans-
porters all belong to the neurotransmitter-sodium-symporter SLC
family (NSS). Thus, a dissipated sodium gradient selectively aug-
ments efﬂux triggered by substrates (Sitte and Freissmuth, 2015).
Afterwards, the cells were exposed to 10 mM 4,40-DMAR or to a
control substance, known to act as transportable substrate of the
respective transporter, for ﬁve fractions. 3 mM para-chloramphet-
amine (PCA) was used for hSERT-expressing cells, 10 mM amphet-
amine for hDAT and hNET and 100 mM GABA for rGAT1-expressing
cells. rGAT1 expressing HEK293 cells were used as a negative con-
trol because amphetamines and amphetamine-type substances
display no activity at GAT1 at pharmacologically relevant concen-
trations (Seidel et al., 2005). Finally, the cells were lysed with 1%
SDS. Afterwards the amount of tritiated substrate present each vial
was determined by a beta-scintillation counter (Perkin Elmer,
Waltham, MA, USA). Efﬂux of tritium was expressed as a fractional
rate, i.e. the radioactivity released during a fraction was expressed
as the percentage of the total radioactivity present in the cells at the
beginning of that fraction.
2.5. Receptor and transporter binding and activation assays
Receptor and transporter binding afﬁnities were determined as
described earlier in detail for each receptor and transporter (Luethi
et al., 2017a). In brief, membrane preparations overexpressing the
respective receptors or transporters (human genes, with the
exception of rat and mouse genes for TAAR1) were incubated with
radiolabeled selective ligands at concentrations equal to Kd, and
ligand displacement by the compounds was measured. Speciﬁc
binding was determined as the difference between total binding
(binding buffer alone) and nonspeciﬁc binding (in the presence of
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determine nonspeciﬁc binding are summarized in Table 1.
The compounds were diluted in binding assay buffer (50mM
Tris/HCl, 10mM MgCl2, 1mM EGTA, pH 7.4). The concentrations
tested ranged from 30 pMe30 mM. Membrane suspension radio-
ligand and test compounds were added to themicroplates (Greiner,
96-well) at a ﬁnal volume of 200 mL per well, incubated and shaken
for 30min at room temperature. The binding reaction was termi-
nated by rapid ﬁltration, using Uniﬁlter-96 plates (Packard Instru-
ment Company, PerkinElmer, Schwerzenbach, Switzerland) and
pre-soaked GF/C glass ﬁlters (incubated for 1 h in 0.3% poly-
ethylenimine, washed with ice-cold washing buffer [50mM Tris/
HCl, pH 7.4]). Afterwards, scintillation cocktail (45 mL/well) was
added and the plates were sealed. One hour later, radioactivity was
determined by a Microplate Scintillation counter (Packard Instru-
ment Company).
FLIPR assays were conducted as previously described (Luethi
et al., 2017a). In brief, HEK293 cells that expressed the human 5-
HT2B receptor were incubated in PDL-coated 96-well plates over-
night. The growth medium was then removed by snap inversion,
and 100 mL of calcium indicator Fluo-4 solution (Molecular Probes,
Eugene, OR, USA) was added to each well. The plates were incu-
bated for 45min at 31 C, the Fluo-4 solution was removed by snap
inversion, and 100 mL of Fluo-4 solution was added a second time
for 45min at 31 C. The cells were then washed and 100 mL assay
buffer was added. Thereafter, the plates were placed in a ﬂuores-
cence imaging plate reader (FLIPR), and 25 mL of the test substances
diluted in assay buffer was added online. The increase in ﬂuores-
cence was measured, and EC50 values were derived from the
concentration-response curves using nonlinear regression. IC50
values were calculated by use of nonlinear regression curves for
one-site models. Ki values were determined via the Cheng-Prusoff
equation (Ki¼ IC50/[1 þ {radioligand concentration/Kd}]). The ex-
periments were conducted as concentration-response curves
covering 10 individual concentrations for at least three times
(n ¼ 3e4).2.6. Data and statistical analysis
IC50, EC50 and AUC values were calculated and plotted with
Microsoft Excel® 2010 (Microsoft Corporation, Redmond,WA, USA)
and GraphPad Prism 7.03 (GraphPad Software Inc., San Diego, CA,
U.S.A.), respectively. Transporter ratios were calculated as (1/
numerator IC50) divided by (1/denominator IC50), e.g. the DAT/SERT
ratio is expressed as (1/DAT IC50) divided by (1/SERT IC50) with
higher values indicating greater selectivity for DAT. Release of
preloaded tritiated substrate in the presence or absence of mon-
ensin was analyzed by repeated measures two-way ANOVA
(treatment x time) and Sidak's test. All results are expressed as
mean± SEM. P values less than 0.05 were considered signiﬁcant.Table 1
Receptors and transporters with their respective radioligands and non-speciﬁc binding d
Receptor rTAAR1 mTAAR1
Radioligand [3H]RO5166017 [3H]RO5166017
Concentration 3.5 nM 2.4 nM
Non-speciﬁc binding 10 mM RO5166017 10 mM RO5166017
Kd 2.8 nM 2.0 nM
Receptor/transporter a1A a2A D2
Radioligand [3H]Prazosin [3H]Rauwolscine [3H]Spipe
Concentration 0.106 nM 2.0 nM 1.16 nM
Non-speciﬁc binding 10 mM chlorpromazine 10 mM phentolamine 10 mM sp
Kd 0.044 nM 2.0 nM 0.26 nM3. Results
3.1. 4,40-DMAR inhibits transporter-mediated uptake in
HEK293 cells
Uptake inhibition experiments were conducted to test whether
4,40-DMAR interacts with human monoamine transporters (i.e.,
hSERT, hDAT, hNET) and rGAT1, expressed in HEK293 cells. As
shown in Fig. 1, 4,40-DMAR is a fully efﬁcacious inhibitor of uptake
mediated by hDAT, hNET and hSERT. No inhibitory effect could be
observed in rGAT1-expressing cells. 4,40-DMAR inhibited hSERT,
hDAT and hNET with equal potency with IC50 values in the low
micromolar range (hSERT¼ 1.75 mMe95% CI: 1.446 to 2.126;
hDAT¼ 1.04 mMe95% CI: 0.848 to 1.282; hNET¼ 0.50 mMe95% CI:
0.447 to 0.553). Calculated ratios emphasize 4,40-DMAR's low
selectivity for one transporter over another (DAT/SERT ratio: 1.68;
NET/SERT ratio: 3.50; DAT/NET ratio: 0.48). In contrast, even the
highest concentration of 4,40-DMAR tested (1000 mM) failed
to achieve half-maximal inhibition of rGAT1-mediated uptake. As a
reference comparator compound, we made use of MDMA
because of its similar proﬁle of action. MDMA inhibited
hSERT (IC50¼16.95 mMe95% CI: 13.41 to 21.43), hDAT
(IC50¼17.62 mMe95% CI: 13.91 to 22.31) and hNET
(IC50¼ 4.57 mMe95% CI: 2.93 to 7.28). We did not conduct uptake
inhibition experiments in rGAT1-expressing cells because we have,
in the same cell line, shown before that MDMA does not interact
with this transporter (Rosenauer et al., 2013).
3.2. 4,40-DMAR induces transporter-mediated release in
HEK293 cells
Data gained from uptake inhibition assays alone are unable to
reveal whether a drug acts as an inhibitor or as a substrate of
transporters (Scholze et al., 2000; Mayer et al., 2016b). Hence, we
performed release assays to investigate whether 4,40-DMAR in-
duces transporter-mediated reverse transport. Dynamic super-
fusion experiments provide a decisive tool to monitor the effects
of test drugs on plasmalemmal transporters (Piﬂ et al., 1995;
Scholze et al., 2000). Cells expressing the transporter of interest
were pre-loaded with radiolabeled substrate and exposed to 4,40-
DMAR (10 mM) in the absence or presence of monensin (10 mM).
Monensin is a Naþ/Hþ ionophore, aiding the inﬂux of sodium into
the cytosol and dissipating the sodium gradient (Scholze et al.,
2000). Thus, monensin selectively augments substrate-induced
release. In contrast, the effects of non-transported inhibitors
remain unchanged (Mayer et al., 2016a; Scholze et al., 2000).
As shown in Fig. 2, the presence of 4,40-DMAR drastically
augmented the basal release of preloaded [3H]substrate via hDAT,
hNET and hSERT. On the contrary, 4,40-DMAR had no effect on the
release of [3H]GABA from rGAT1 expressing cells. Two-way ANOVA
(monensin treatment x time) revealed that monensin treatmentetermining substances, as used for radioligand binding assays.
5-HT1A 5-HT2A 5-HT2C
[3H]-8-OH-DPAT [3H]Ketanserin [3H] Mesulergine
0.9 nM 0.4 nM 1.4 nM
10 mM pindolol 10 mM spiperone 10 mM mianserin
1.39 nM 0.45 nM 1.6 nM
hDAT hNET hSERT
rone [3H]WIN35,428 N-methyl-[3H]Nisoxetine [3H]Citalopram
3.3 nM 2.9 nM 1.5 nM
iperone 10 mM indatraline 10 mM indatraline 10 mM indatraline
30 nM 37 nM 20 nM
Fig. 1. Effects of (±)-cis-4,40-dimethylaminorex (4,40-DMAR) and 3,4-methylendioxymethylamphetamine (MDMA) on transporter-mediated uptake in HEK293 cells expressing
hSERT, hDAT, hNET and rGAT1, respectively. (A) The chemical structure of 4,40-DMAR. (BeE) Uptake of the indicated tritiated substrate into cells expressing the indicated trans-
porters was determined in the presence of increasing concentrations of 4,40-DMAR and MDMA. All symbols represent mean values ± SEM. The following numbers indicate the
number of individual experiments with 4,40-DMAR, performed in triplicate: hSERT: 5; hDAT: 5; hNET: 8; rGAT1: 8. The following numbers indicate the number of individual
experiments with MDMA, performed in triplicate or duplicate: hSERT: 5; hDAT: 4; hNET: 6.
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Fig. 2. Effects of 4,40-DMAR on transporter-mediated release of preloaded radiolabeled substrate from HEK293 cells expressing hSERT, hDAT, hNET and rGAT1, respectively. (AeD)
Effects of 4,40-DMAR on transporter-mediated efﬂux of tritiated substrates in HEK293 cells expressing monoamine transporters. After three basal fractions monensin or vehicle was
added at t ¼ 6 min (MON, 10 mM, indicated by black bar). Subsequently, the cells were exposed to 4,40-DMAR at t ¼ 12 min (indicated by arrow and bar). All data are represented as
mean ± SEM. Data were analyzed by repeated measures two-way ANOVA followed by Sidak's test. * Denotes p < 0.05 when compared to vehicle. The following numbers indicate the
number of individual experiments performed in triplicate: hSERT: 5; hDAT: 5; hNET: 5; rGAT1: 5.
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presence of 4,40-DMAR in DAT, NET and SERT expressing cells. The
effect of treatment at hDAT was F1,26¼ 4.25, P< 0.05, for hNET it
was F1,25¼ 24.7, P< 0.05 and for hSERT it was F1,28¼ 373.22,
P< 0.05. On the other hand, the results at rGAT1 (F1,24¼ 0.3,
P¼ 0.59) revealed that monensin did not affect the effects of 4,40-
DMAR on rGAT1. For a comparison with control substances see
Fig. 5 in the appendix.3.3. 4,40-DMAR binds to monoamine transporters
The binding afﬁnities (and activation potency at 5HT2B) of
4,40-DMAR are listed in Table 2. 4,40-DMAR did not bind to
rTAAR1, mTAAR1, 5HT1A, a1A, a2A and D2 at the tested concen-
trations. 4,40-DMAR bound to 5-HT2A and 5-HT2C at higher con-
centrations with Ki values of 8.8 ± 0.9 mM and 11.1 ± 0.6 mM
respectively. As shown in Table 2, 4,40-DMAR binds to the
monoamine transporters hDAT, hNET and hSERT with signiﬁ-
cantly higher binding afﬁnities when compared to monoaminereceptors. One-way ANOVA (Tukey's multiple comparisons test)
revealed that the Ki difference between 5HT2A and 5HT2C and the
monoamine transporters is signiﬁcant (p < 0.0001) but the dif-
ferences between the transporters' Ki values are only signiﬁcant
when hNET and hSERT are compared (p < 0.05 [a comparison of
hDAT and hSERT yields a p value of 0,053]).3.4. 4,40-DMAR inhibits VMAT2 uptake in rat PC12 cells
To investigate whether 4,40-DMAR inhibits rVMAT2, we per-
formed uptake inhibition assays in PC12 cells that endogenously
express rVMAT2 on monoaminergic vesicles. We found that reser-
pine, MDMA and 4,40-DMAR inhibited rVMAT2 in a concentration-
dependent manner (Fig. 3). Reserpine inhibited rVMAT2 with an
IC50 value of 0.043 mM (95% CI: 0.028 mMe0.067 mM). MDMA and
4,40-DMAR were much weaker in that regard, with IC50 values of
26.47 mM (95% CI: 17.45 to 39.9) and 29.28 mM (95% CI: 16.29 to
52.61), respectively.
Table 2
Receptor and transporter binding afﬁnities and 5-HT2B activation potencies of (as determined by FLIPR assay) of 4,40-DMAR. Ki and EC50 values are given in nM (mean± SD).
Receptor rTAAR1 mTAAR1 5-HT1A 5-HT2A 5-HT2B 5-HT2C
Receptor binding Receptor binding Receptor binding Receptor binding Activation potency Receptor binding
Ki± SD [nM] Ki± SD [nM] Ki± SD [nM] Ki± SD [nM] EC50± SD [nM] Ki± SD [nM]
>5010 >4740 >17,400 8846± 862.6 >10,000 11,068± 561.1
Receptor/Transporter a1A a2A D2 hDAT hNET hSERT
Receptor binding Receptor binding Receptor binding Transporter binding Transporter binding Transporter binding
Ki± SD [nM] Ki± SD [nM] Ki± SD [nM] Ki± SD [nM] Ki± SD [nM] Ki± SD [nM]
>2120 >4970 >13,500 533.8± 44.2 266.8± 57 1881± 183.1
Fig. 3. Effects of 4,40-DMAR, MDMA and reserpine on rVMAT2-mediated uptake in
PC12 cells. Uptake inhibition experiments were performed as described in section 2.3.
All symbols represent mean values± SEM. The following numbers indicate the number
of individual experiments performed in triplicate: 4,40-DMAR: 8; MDMA: 8; reserpine:
5.
Fig. 4. Effects of 4,40-DMAR, MDMA and reserpine on VMAT2-mediated uptake in
human striatal synaptic vesicles. Uptake was determined as described in section 2.3.
Symbols represent mean values ± SEM. Control uptake was 18.6± 2.7 pmol x 4 min1 x
mg protein1. The data of each experiment were ﬁtted by nonlinear regression
assuming a Hillslope of 1. The following numbers indicate the number of individual
experiments performed in duplicate: 4,40-DMAR: 6; MDMA: 7; reserpine: 4.
J. Maier et al. / Neuropharmacology 138 (2018) 282e2912883.5. 4,40-DMAR inhibits VMAT2-mediated uptake in human striatal
synaptic vesicles
Finally, we conducted uptake inhibition experiments in synaptic
vesicles prepared from human striatum. The experiments were
performed in sodium-free potassium phosphate buffer (Piﬂ et al.,
2014). Fig. 4 shows that 4,40-DMAR inhibits [3H]dopamine uptake
by human VMAT2 in the micromolar range (IC50¼27.6± 7.7 mM),
comparable to MDMA (IC50¼28.3± 4.1 mM), but much less potently
than reserpine (IC50¼0.044± 0.006 mM).
4. Discussion
The main intention of the present study was to determine the
pharmacodynamic effects of (±)-cis-4,40-dimethylaminorex on
monoamine receptors and transporters since only two studies are
available on 4,40-DMAR (Brandt et al., 2014; McLaughlin et al.,
2015). Both studies used rat brain synaptosomes to determine the
releasing effects of 4,40-DMAR at monoamine transporters. There-
fore, we set out to gain information on the effects of 4,40-DMAR on
the human isoforms of DAT, NET and SERT, focusing on uptake in-
hibition and transporter release experiments, as well as deter-
mining its interaction with monoamine transporters and receptors
in binding assays. Moreover, we included rat and human VMAT2 in
our study since perturbations of VMAT2 function appear to be
associated with the long-term toxicity of drugs of abuse (German
et al., 2015). This study adds important insights to the existing
knowledge on the effects of 4,40-DMAR in humans. So far, knowl-
edge is limited to subjective drug user reports (Loi et al., 2017). Bycorroborating the results garnered from ex vivo rat brain studies
obtained in synaptosomes, the ﬁndings of this study certainly
strengthen the translational relevance of rodent models for ana-
lyses of the properties of psychostimulant drugs.
Uptake inhibition experiments demonstrated that 4,40-DMAR
inhibited inwardly-directed transport mediated by hNET, hDAT and
hSERT with comparable potencies. We have also shown that it is a
more potent inhibitor of uptake in monoamine transporters than
MDMA. To test whether 4,40-DMAR acts an inhibitor or as a
substrate-type releaser, we investigated the effect of the drug on
carrier-mediated reverse transport. Administration of monensin
signiﬁcantly augmented 4,40-DMAR evoked release at all three
monoamine transporters. We have previously shown that the Naþ/
Hþ ionophore monensin only augments release triggered by sub-
strates, but not inhibitors (Mayer et al., 2016a; Steinkellner et al.,
2016; Baumann et al., 2013; Scholze et al., 2000). Hence, these
data strongly argue against the possibility that the apparent drug-
induced release of tritiated substrates simply represents inhibition
of uptake, i.e. “unmasking” of basal substrate leakage. This inter-
pretation is supported by the fact that monensin had no inﬂuence
on an effect of 4,40-DMAR on rGAT1-expressing cells but markedly
enhanced the releasing effect of the physiological rGAT1-substrate
GABA. Similarly, McLaughlin et al. (2015), using rat brain synapto-
somes, demonstrated that 4,40-DMAR is an equipotent releaser at
DAT, NET, and SERT with higher potencies compared to the non-
selective releaser MDMA. Brandt et al. (2014) have compared the
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found that the potencies at DAT and NET were comparable to
aminorex but less potent than 4-MAR. In contrast, the highest po-
tency to induce 5-HT release via SERT was observed with 4,40-
DMAR. Numerous publications show that ring-substitution in the
para-position renders substrate-type releasers less selective for
DAT over SERT (Mayer et al., 2017; Solis et al., 2017; Bonano et al.,
2015; Sakloth et al., 2015; Cozzi et al., 2013). It is striking that the
binding/uptake ratio of 4,40-DMAR is close to unity, which has been
recently shown to generally be the case for uptake inhibitors but
not substrates (Eshleman et al., 2017). Nevertheless, previous
research from our laboratory suggests that drugs acting on mono-
amine transporters may alter in adopting either substrate-type or
inhibitory binding modes (Sandtner et al., 2016). Furthermore, a
lack in conformity between uptake inhibition and radioligand
binding assays under varied conditions has previously been
observed for pure uptake inhibitors (Luethi et al., 2017b). Our re-
sults therefore describe a unique proﬁle of the investigated sub-
stance 4,40-DMAR.
Only one death due to 4-methylaminorex (4-MAR) (Davis and
Brewster, 1988) and several cases of pulmonary hypertension
caused by aminorex and 4-MAR (Rothman et al., 1999; Gaine et al.,
2000) have been reported. Rothman et al. (1999) attribute these to
the pronounced effect on 5-HT; most likely, this effect could be
attributed to 5-HT2 receptors (Lauder et al., 2000). The admission
notes and autopsy reports of 4,40-DMAR related deaths (EMCDDA,
2015), suggest clinical features consistent with serotonin toxicity
(Greenier et al., 2014). Cardiotoxicity appears to be related to the
effects on extracellular norepinephrine, as well as 5-HT (Brandt
et al., 2014; Baumann and Rothman, 2009; Lauder et al., 2000).
Similar effects and mechanisms have been reported for MDMA
(Hysek et al. 2011, 2012; Piﬂ et al., 2005; Liechti and Vollenweider,
2000).
It must be noted that the neurotoxicity of 4-MAR has already
been subject of great controversy. On the one hand, long-term
damage to serotonergic and dopaminergic axons has been re-
ported (Bunker et al., 1990; Hanson et al., 1992), but could not be
reproduced in another study (Zheng et al., 1997).
Perturbation of VMAT2-function has been linked to neurotox-
icity. Hence, we sought to examine the effects of 4,40-DMAR on
VMAT2. We used rat PC12 cells, which endogenously express
rVMAT2, and vesicles prepared from human striatum. We found
that 4,40-DMAR inhibited the rat and human isoforms of VMAT2.
For both species, the potencies were comparable to those of MDMA.
Empirical data bolster the hypothesis that inhibition of VMAT2
might be responsible for long-term neurotoxicity (Lohr et al., 2015;
Piﬂ et al., 2015). Furthermore, substrate-activity and transporter-
associated currents have been linked to depletion of 5-HT by fen-
ﬂuramine in serotonergic neurons (Baumann et al., 2014). Hence,
one might speculate that dual substrate activity at plasmalemmal
and vesicular transporters results in neurotoxicity (Freyberg et al.,
2016; Chaudhry et al., 2007). Future studies on NPS should
include assays to determine activity at VMAT2 to provide a detailed
understanding of the substances' effects on monoamine
transporters.
VMAT2 and ABCB1 (P-glycoprotein, MDR1) are co-expressed in
endothelial cells lining up the blood-brain barrier. They share
sequence homology and cross-reactivity of a number of inhibitors,
e.g. reserpine (Staal et al., 2001). Therefore, 4,40-DMAR-attributed
inhibition of VMAT2-mediated uptake hints at the possibility of a
potential ABCB1-inhibition (Staal et al., 2001): This can facilitate
the entry of drugs through the blood-brain barrier, which ﬁnally
leads to accumulation in neurons and increased neurotoxic effects
(Schinkel, 1999). The recently described increased brain-to-plasma
ratio of 4,40-DMAR in comparison to its parent substances, mightpotentially be caused by 4,40-DMAR's interaction with ABCB1, at
least in part (Lucchetti et al., 2017).
The results of this paper are highly relevant. Even though 4,40-
DMAR has been placed under international control, it still appears
to be advertised for sale from Internet retailers (e.g., Shenzhen
Chemicals, 2018). According to the EMCDDA (2015), 4,40-DMAR
was often consumed unintentionally as an adulterant that was
added to MDMA or cocaine, possibly to increase revenues to drug
dealers (Brunt et al., 2017; Gine et al., 2014). Similar reports are
available for 4-MAR, which has been sold as cocaine or metham-
phetamine (Meririnne et al., 2004). Experimental ﬁndings pre-
sented in Brandt et al. (2014), McLaughlin et al. (2015) and the
present study suggest that 4,40-DMAR resembles the pharmaco-
logical proﬁle of MDMA and acts as a non-selective monoamine
transporter releasing agent which also affects VMAT2. 4,40-DMAR
might also be considered a more serotonergic drug than the closely
related substances 4-MAR and aminorex. The in vitro study carried
out in rat brain synaptosomes reported by McLaughlin et al. (2015)
conﬁrmed that 4,40-DMAR was a more potent releaser than MDMA
across all three transporters. The transporter binding experiments
results presented in this study indicate that 4,40-DMAR exhibits
higher binding afﬁnities than MDMA (Simmler et al., 2013, 2014).
Receptor-binding experiments suggest that 4,40-DMAR exhibits
noe or if at all only poor-afﬁnity towards mouse and rat TAAR1. On
the contrary, sub- (rat) and low-micromolar (mouse) afﬁnities to-
wards TAAR1 have been reported for MDMA (Simmler et al., 2013).
The exact role of TAAR1 in amphetamine action remains far from
being completely understood (Sitte and Freissmuth, 2015). How-
ever, TAAR1 appears to exert auto-inhibitory effects on mono-
aminergic neurons, thus regulates the release of the corresponding
monoamines (Revel et al., 2011, 2012). TAAR1 is activated by a
subset of amphetamines (Simmler et al., 2016). This observation
has been linked to auto-inhibitory and neuroprotective effects of
TAAR1 in amphetamine action (Miner et al., 2017; Revel et al., 2012;
DiCara et al., 2011; Lindemann et al., 2008). The lack of agonist-
activity at TAAR1 might further contribute to long-term toxicity
of 4,40-DMAR, thus representing an interesting ﬁeld for future in-
vestigations. Some binding was observed at 5HT2A and 5HT2C re-
ceptors. The afﬁnity towards 5HT2A (Ki¼ 8.8 mM) is rather low and
comparable to the afﬁnity reported for MDMA (Ki¼ 5.9 mM)
(Simmler et al., 2013). Interestingly, the 5-HT2 subgroup of re-
ceptors (5-HT2A, 5-HT2B and 5-HT2C), expressed not only in the CNS,
but amongst other peripheral regions, also in the myocardium,
endocardium and the heart valves, is implicated in cardiovascular
complications (Baumann and Rothman, 2009; Lauder et al., 2000).
It has been suggested for MDMA that binding to the 5-HT2B re-
ceptor is associated with an increased occurrence of valvular heart
disease (Baumann and Rothman, 2009). Even though 4,40-DMAR
only binds to 5-HT2A and 5-HT2C receptors with lower afﬁnities, this
mechanism might be, in part, implicated in long-term cardiac
complications.
While there is now accumulating knowledge on the in vitro
pharmacodynamic effects of 4,40-DMAR, its pharmacokinetic
properties in humans remain to be determined. However, Lucchetti
et al. (2017) have recently evaluated the pharmacokinetic proper-
ties in male Wistar rats: They located four metabolites, determined
that 4,40-DMAR is lipophilic enough to easily cross the blood-brain
barrier. In addition, the substance was shown (i) to increase
spontaneous locomotor activity and (ii) to cause positive motiva-
tional and addictive effects in rats (Lucchetti et al., 2017). The latter
ﬁnding can be corroborated by the high releasing potency at hDAT,
as conﬁrmed by the current study. In contrast, MDMA's pharma-
cokinetic properties in humans have been studied in more detail
(De la Torre et al., 2004; Kolbrich et al., 2008). Future animal model
studies should explore the potential short-term cardiotoxic and
J. Maier et al. / Neuropharmacology 138 (2018) 282e291290long-term neurotoxic effects of 4,40-DMAR, discussed in this study,
in vivo.
The NPS market is exceedingly dynamic. Hence, the information
presented herein might be relevant for our understanding for other
aminorex derivatives that may be introduced into the drug markets
(McLaughlin et al., 2015). Serotonin syndrome and noradrenergic
sympathomimetic effects have been associated with the lethal 4,40-
DMAR intoxications. These insights lend support to medical pro-
fessionals to treat drug users appropriately. Considering our current
understanding of the pharmacology of MDMA and 4,40-DMAR, it
appears unlikely that the adverse effects reported for 4,40-DMAR
are attributable to its interaction with a single molecular target.
Data available so far rather suggest that the clinically adverse ef-
fects result from overdosing, for example, when 4,40-DMAR has
been mistaken with another drug, be it unintentionally or during
the process of adulteration. This emphasizes the important role of
harm reduction initiatives, such as the Trans European Drug In-
formation (TEDI) project, where drug users can get their purchased
substances, anonymously and without the threat of legal re-
percussions, chemically analyzed and are informed about the in-
gredients and the toxicity associated therewith (Brunt et al., 2017).
In addition, this strategy allows the collection of temporally
resolved insights into the drug markets (Brunt et al., 2017). This
might aid the prevention of further drug-related tragedies such as
the 4,40-DMAR-caused series of deaths between June 2013 and
February 2014 (EMCDDA, 2015).5. Conclusion
The new psychoactive substance 4,40-DMAR has been shown to
be a potent non-selective monoamine transporter releasing agent
that inhibits VMAT2-mediated uptake in human and rat cells. The
latter result might explain its potential long-term neurotoxicity,
caused by the accumulation of substrate in the cytosol. Compared
to other amphetamine-type stimulants and its predecessors, 4,40-
DMAR has a very pronounced serotonergic proﬁle of action similar
to MDMA. However, 4,40-DMAR was often mislabeled and sold as
ecstasy, albeit it is a more potent releasing agent. The deaths can
therefore be apprehended as overdoses, acutely causing serotonin
and norepinephrine toxicity.Conﬂicts of interest
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